Physician profile
Purvisha Patel
NPI 1174637433
$19,520.25
in general payments reported to CMS, 2019-2025
47 companies · $1,851 in 2025
The $1,851 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,329 · 2020: $3,122 · 2021: $3,323 · 2022: $4,645 · 2023: $1,797 · 2024: $2,454 · 2025: $1,851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,908 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,907.87 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $8,153.07 | 2019-2024 | Xeomin |
| Abbvie INC. | $2,095.35 | 2019-2025 | |
| Pfizer INC. | $1,189.29 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,117.33 | 2019-2025 | |
| Janssen Biotech, INC. | $767.21 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $625.73 | 2020-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $588.56 | 2022-2025 | Sotyktu |
| Revance Therapeutics, INC. | $467.37 | 2024-2025 | Daxxify |
| Galderma Laboratories, L.P. | $448.65 | 2019-2025 | Nemluvio, Dysport |
| Medimetriks Pharmaceuticals, INC. | $435.75 | 2019-2024 | Neo-Synalar |
| Regeneron Healthcare Solutions, INC. | $395.33 | 2019-2024 | Dupixent |
| Lilly USA, LLC | $362.77 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $339.97 | 2019-2025 | |
| Kerecis Limited | $292.27 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $254.74 | 2019-2022 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $243.32 | 2020-2025 | Bimzelx |
| Organogenesis INC. | $181.09 | 2020-2025 | Novachor, Puraply, Cygnus Dual |
| Leo Pharma INC. | $180.17 | 2019-2025 | Adbry |
| Misonix INC | $144.04 | 2021 | |
| Epi Health, LLC | $114.34 | 2022 | |
| Genentech USA, INC. | $108.05 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $78.97 | 2021 | |
| Sensus Healthcare, INC. | $76.56 | 2019-2024 | |
| Incyte Corporation | $69.60 | 2021-2024 | Opzelura |
| Kowa Pharmaceuticals America, INC. | $67.25 | 2022 | |
| Dermavant Sciences, INC. | $66.17 | 2024 | Vtama |
| Organon LLC | $54.71 | 2025 | Vtama |
| Botanix Sb INC | $54.45 | 2025 | Sofdra |
| Novo Nordisk INC | $50.00 | 2024 | Wegovy |
| Allergan, INC. | $47.43 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $41.52 | 2019 | |
| Amgen INC. | $41.32 | 2021-2023 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.63 | 2023 | Cyltezo, Spevigo |
| Biofrontera INC. | $40.32 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Arcutis Biotherapeutics, INC. | $39.69 | 2024-2025 | Zoryve |
| Prugen, INC. Pharmaceuticals | $35.96 | 2020 | |
| Dermira, INC. | $33.37 | 2020-2021 | |
| Kyowa Kirin, INC. | $28.23 | 2024 | Poteligeo |
| Mayne Pharma Commercial LLC | $24.94 | 2019 | |
| Reprise Biomedical, INC. | $21.95 | 2025 | Miro3d |
| Sandoz INC. | $21.15 | 2023 | Hyrimoz |
| Stemline Therapeutics INC. | $16.75 | 2020 | |
| Paratek Pharmaceuticals, INC. | $16.54 | 2025 | Nuzyra |
| Nabriva Therapeutics, Plc | $13.99 | 2022 | |
| Qiagen, LLC | $12.50 | 2020 | |
| Celgene Corporation | $12.01 | 2019 | |
| Journey Medical Corporation | $9.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$16,780.15 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Purvisha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.